7 February 2019
Dear patients, shareholders, friends,
In this second Communiqué for the year we will delve deeper in the ongoing treatment of erythropoietic protoporphyria (EPP) patients in Europe and look ahead at the expected news flow from the US Food and Drug Administration (FDA) in the coming months.
Gradually, we are sharing the contours of the Company (see the notes to “AGM 2018”: CUV by 2021) and discussing our progress towards expanding the Company…